William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating
William Blair analyst Andy Hsieh initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Outperform rating.
Read original at benzingaStocks · News reference
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 18, 2026, 5:58 PM
- Checked
- Aug 18, 2026, 5:58 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78
Barclays analyst Etzer Darout initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $78.
Read original at benzingaMizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $73
Mizuho analyst Salim Syed maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and raises the price target from $62 to $73.
Read original at benzingaAI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players
Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.
Read original at globenewswire-incNovartis India Approves Termination Of Distribution Agreement With Dr. Reddy’s Laboratories; Termination Agreement With Dr. Reddy’s Effective September 30, 2026; To Re-Buy Exclusivity And Market Access For Products After DRL Agreement Termination
- Reuters
Read original at benzingaPrecision Medicine Collaboration and Licensing Deals 2019-2026 | Gain Access to Over 1,350 Deals and Benchmark with Confidence
ResearchAndMarkets.com released a comprehensive report analyzing 1,350+ precision medicine collaboration and licensing deals from 2019-2026. The report provides detailed benchmarking data on deal structures, financial terms, and contract provisions to support business development and strategy decisions in the precision medicine sector.
Read original at globenewswire-inc